· Desk editor: Nadia Hassan · · Single source

Isomorphic Labs raises $5 billion for AI drug discovery

Isomorphic Labs secured $5 billion in Series C funding to advance its AI-driven drug candidates toward clinical trials.

Funding round details and investors

The company raised the capital with Greenoaks and Sequoia Capital co-leading the round. New investor Andreessen Horowitz joined alongside existing backers like Alphabet's GV and Capital G. Additional attendees comprised MGX, Thrive Capital, Temasek, as well as the UK Sovereign AI Fund. This Series C follows a $2.1 billion Series B round completed in May. The total funding will support engine development and expansion into new medicine types.

Company background and technology

Isomorphic Labs spun out of Google's DeepMind in 2021 under founder Demis Hassabis. Its AI engine uses simulation models to explore chemistry areas for drug design. The platform builds on the AlphaFold model which won a Nobel Prize in chemistry. Hassabis left his head role at DeepMind to focus entirely on drug discovery. He now serves as chairman while John Jumper remains as director.

Partnerships and preclinical results

The firm has struck deals with pharma giants including Eli Lilly, Novartis, and Johnson & Johnson. Isomorphic stated its program yielded positive preclinical results in oncology and immunology fields. The new funds will allow the team to continue developing their proprietary design engine. Bloomberg reported earlier this month that the lab sought funding at a $50 billion valuation. The company did not disclose its current valuation after this latest round.

Reported by one outlet

Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.

Reported by

1 independent outlet. Headline as published. Links open the original report.